BRPI0416248A - métodos para determinar se um paciente resistente a insulina é um respondedor a um tratamento terapêutico para resistência a insulina, e para predizer se um tratamento terapêutico para resistência a insulina será efetivo na melhoria de uma ou mais doenças associadas com resistência a insulina - Google Patents

métodos para determinar se um paciente resistente a insulina é um respondedor a um tratamento terapêutico para resistência a insulina, e para predizer se um tratamento terapêutico para resistência a insulina será efetivo na melhoria de uma ou mais doenças associadas com resistência a insulina

Info

Publication number
BRPI0416248A
BRPI0416248A BRPI0416248-0A BRPI0416248A BRPI0416248A BR PI0416248 A BRPI0416248 A BR PI0416248A BR PI0416248 A BRPI0416248 A BR PI0416248A BR PI0416248 A BRPI0416248 A BR PI0416248A
Authority
BR
Brazil
Prior art keywords
therapeutic treatment
insulin resistance
insulin
adiponectin
amount
Prior art date
Application number
BRPI0416248-0A
Other languages
English (en)
Inventor
John A Wagner
Philipp E Scherer
Utpal B Pajvani
Original Assignee
Merck & Co Inc
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Einstein Coll Med filed Critical Merck & Co Inc
Publication of BRPI0416248A publication Critical patent/BRPI0416248A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

"MéTODOS PARA DETERMINAR SE UM PACIENTE RESISTENTE A INSULINA é UM RESPONDEDOR A UM TRATAMENTO TERAPêUTICO PARA RESISTêNCIA A INSULINA, E PARA PREDIZER SE UM TRATAMENTO TERAPêUTICO PARA RESISTêNCIA A INSULINA SERá EFETIVO NA MELHORIA DE UMA OU MAIS DOENçAS ASSOCIADAS COM RESISTêNCIA A INSULINA". Um paciente que é um respondedor a um tratamento terapêutico para resistência a insulina ou para uma ou mais doenças associadas com diabetes de tipo 2 pode ser identificado pelo método de medir a quantidade de adiponectina de PMA e a quantidade de adiponectina total ou adiponectina de PMB no tecido do paciente (normalmente plasma ou soro) antes de começar o tratamento terapêutico; então começar o tratamento terapêutico; e finalmente medir a quantidade de adiponectina de PMA e a quantidade de quer adiponectina total quer adiponectina de PMB no plasma ou soro do paciente uma ou mais vezes após o começo do tratamento terapêutico. é predito que o paciente é respondedor ao tratamento terapêutico se a razão da de adiponectina de PMA para a quantidade de adiponectina total ou adiponectina de PMB aumentar após começar o tratamento terapêutico.
BRPI0416248-0A 2003-11-07 2004-11-04 métodos para determinar se um paciente resistente a insulina é um respondedor a um tratamento terapêutico para resistência a insulina, e para predizer se um tratamento terapêutico para resistência a insulina será efetivo na melhoria de uma ou mais doenças associadas com resistência a insulina BRPI0416248A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51839003P 2003-11-07 2003-11-07
PCT/US2004/036648 WO2005046734A1 (en) 2003-11-07 2004-11-04 Method of identifying responders to treatment with insulin sensitizers

Publications (1)

Publication Number Publication Date
BRPI0416248A true BRPI0416248A (pt) 2007-01-09

Family

ID=34590257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416248-0A BRPI0416248A (pt) 2003-11-07 2004-11-04 métodos para determinar se um paciente resistente a insulina é um respondedor a um tratamento terapêutico para resistência a insulina, e para predizer se um tratamento terapêutico para resistência a insulina será efetivo na melhoria de uma ou mais doenças associadas com resistência a insulina

Country Status (10)

Country Link
US (1) US20070098636A1 (pt)
EP (1) EP1684807B1 (pt)
JP (1) JP4397934B2 (pt)
CN (1) CN1882363A (pt)
AT (1) ATE441437T1 (pt)
AU (1) AU2004289237C1 (pt)
BR (1) BRPI0416248A (pt)
CA (1) CA2545065C (pt)
DE (1) DE602004022968D1 (pt)
WO (1) WO2005046734A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008273938A (ja) * 2007-03-30 2008-11-13 Shiseido Co Ltd アディポネクチン産生促進剤
US20080312154A1 (en) * 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
EP2156191A2 (en) * 2007-06-15 2010-02-24 Smithkline Beecham Corporation Methods and kits for predicting treatment response in type ii diabetes mellitus patients
WO2009070350A1 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
WO2010067207A1 (en) * 2008-12-11 2010-06-17 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
US20100209350A1 (en) * 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
CN102388308B (zh) 2009-04-23 2015-08-19 西门子医疗保健诊断公司 单体和二聚形式的脂连蛋白受体片段和使用方法
JP7116413B2 (ja) * 2018-03-02 2022-08-10 株式会社山田養蜂場本社 選別方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016906A1 (fr) 2001-08-17 2003-02-27 Rebio Gen, Inc. Procede de diagnostic ou de controle d'une erreur du metabolisme du saccharose
CN1867828B (zh) * 2003-10-15 2010-09-29 第一化学药品株式会社 脂连蛋白多聚体的分离测定方法

Also Published As

Publication number Publication date
JP4397934B2 (ja) 2010-01-13
EP1684807B1 (en) 2009-09-02
CA2545065C (en) 2012-07-17
CN1882363A (zh) 2006-12-20
JP2007510906A (ja) 2007-04-26
AU2004289237C1 (en) 2009-02-26
CA2545065A1 (en) 2005-05-26
EP1684807A4 (en) 2008-03-19
US20070098636A1 (en) 2007-05-03
DE602004022968D1 (de) 2009-10-15
EP1684807A1 (en) 2006-08-02
WO2005046734A1 (en) 2005-05-26
AU2004289237A1 (en) 2005-05-26
AU2004289237B2 (en) 2008-08-21
ATE441437T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
Adler et al. Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study
Hamer et al. Association between physical fitness, parasympathetic control, and proinflammatory responses to mental stress
Aoike et al. Impact of home-based aerobic exercise on the physical capacity of overweight patients with chronic kidney disease
Mackenzie et al. Intermittent exercise with and without hypoxia improves insulin sensitivity in individuals with type 2 diabetes
Rosety-Rodriguez et al. Low-grade systemic inflammation and leptin levels were improved by arm cranking exercise in adults with chronic spinal cord injury
Petersen et al. Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training
Fanavoll et al. Psychosocial work stress, leisure time physical exercise and the risk of chronic pain in the neck/shoulders: Longitudinal data from the Norwegian HUNT Study
Demirel et al. Risk factors for coronary heart disease in patients with spinal cord injury in Turkey
Petrofsky et al. The efficacy of sustained heat treatment on delayed-onset muscle soreness
NZ598732A (en) Dosage regimen for administering a cd19xcd3 bispecific antibody
Pieruccini‐Faria et al. Mapping associations between gait decline and fall risk in mild cognitive impairment
Mitchell et al. Propofol as an anaesthetic agent for ECT: effect on outcome and length of course
Cummings et al. Fitness versus fatness and insulin resistance in US adolescents
BRPI0416248A (pt) métodos para determinar se um paciente resistente a insulina é um respondedor a um tratamento terapêutico para resistência a insulina, e para predizer se um tratamento terapêutico para resistência a insulina será efetivo na melhoria de uma ou mais doenças associadas com resistência a insulina
Yuan et al. Comparing the effects of 6 months aerobic exercise and resistance training on metabolic control and β‐cell function in Chinese patients with prediabetes: a multicenter randomized controlled trial
NO975492D0 (no) Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet
Jimenez et al. Predicting improvement in stroke patients referred for inpatient rehabilitation.
Meng et al. Effects of circadian rhythm disorder on body composition in women aged 31–40 years
Kubo et al. Worsening renal function during hospitalization in elderly patients with heart failure: an independent factor of activities of daily living decline
Jacobsson et al. Evaluation of a structured multidisciplinary day care program in rheumatoid arthritis: a similar effect in newly diagnosed and long-standing disease
Pattayil et al. Proportional relationship between periodontal inflamed surface area, clinical attachment loss, and glycated hemoglobin level in patients with type 2 diabetes mellitus on insulin therapy and on oral antidiabetic therapy
Lai et al. Substituting sedentary time with physical activity in youngest-old to oldest-old community-dwelling older adults: Associations with body composition
Palareti et al. Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
Kubo et al. Factors delaying the progress of early rehabilitation of elderly Japanese patients with heart failure
Jamka et al. Comparison of the effects of endurance and endurance‑strength training programmes on the level of endothelial dysfunction in women with abdominal obesity: study protocol for a randomised controlled trial: A study protocol of the ENDOFIT study

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

Free format text: ALTERADO DE: MERCK AND CO., INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B25D Requested change of name of applicant approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B25G Requested change of headquarter approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.